Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 36Active not recruiting 9Completed 5Not yet recruiting 3Terminated 2Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Endometrial Neoplasms 1Advanced Solid Tumor 1Advanced Bladder Cancer 1

Interventions

Specimen Handling 79Bevacizumab 66Drug Therapy 65Cisplatin 64Carboplatin 63Magnetic Resonance Spectroscopy 61Radiotherapy 57Cyclophosphamide 55Gemcitabine 54pembrolizumab 53Oxaliplatin 50Capecitabine 50toripalimab 42Paclitaxel 41tislelizumab 40Standard of Care 40Biopsy 37fludarabine 36Fluorouracil 35venetoclax 33Injections 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 29Nivolumab 29Surgical Procedures, Operative 28Irinotecan 27Docetaxel 27Dexamethasone 27Leucovorin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × enfortumab vedotin × 1 year × Clear all
NCT07139977 2026-01-20

EV-4-EC

Medical College of Wisconsin

Phase 2 Not yet recruiting
12 enrolled
Gynecologic

Endometrial Neoplasms

NCT07346053 2026-01-16

Chrono-EVP

British Columbia Cancer Agency

Phase 3 Not yet recruiting
224 enrolled
Genitourinary

Advanced Bladder Cancer

NCT07157956 2025-09-05

CVL006-T1002

Convalife (Shanghai) Co., Ltd.

Phase 1/2 Not yet recruiting
318 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡